Skip to main content
Biofil Chemicals & Pharmaceuticals logo

Biofil Chemicals & Pharmaceuticals — Investor Relations & Filings

Ticker · BIOFILCHEM ISIN · INE829A01014 LEI · 89450040Q8MG7L3DZG70 BSE.NS Manufacturing
Open in API
Filings indexed 490 across all filing types
Latest filing 2026-05-23 Regulatory Filings
Country IN India
Listing BSE.NS BIOFILCHEM

About Biofil Chemicals & Pharmaceuticals

https://www.biofilgroup.net

Biofil Chemicals & Pharmaceuticals is a pharmaceutical enterprise focused on the manufacturing and distribution of a diverse range of pharmaceutical formulations and bulk drugs. The company operates through specialized divisions, including a Pharma Division and a Chemicals Division. Its product portfolio encompasses various therapeutic categories, featuring tablets, capsules, liquid orals, and dry syrups, with a particular emphasis on antibiotics, anti-infectives, and nutritional supplements. In addition to its core pharmaceutical operations, the company maintains manufacturing capabilities for plastic products, specifically targeting the packaging requirements of the healthcare sector. Biofil emphasizes adherence to quality control standards and utilizes advanced manufacturing processes to serve both domestic and international markets, providing essential healthcare solutions through a robust supply chain and distribution network.

Recent filings

Filing Released Lang Actions
Submission of Annual Secretarial Compliance Report for the Financial year ended 31st March 2026
Regulatory Filings Classification · 85% confidence The document is an Annual Secretarial Compliance Report submitted under Regulation 24A of SEBI (LODR). It is a compliance certificate prepared by Practicing Company Secretaries detailing compliance with listing regulations, not an annual financial or management report itself. It does not contain substantive financial statements, nor is it simply announcing publication of another report. Therefore, it falls under general regulatory filings (compliance documents) rather than a specific financial report category.
2026-05-23 English
Biofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Audited ....
Regulatory Filings Classification · 75% confidence The document is an official intimation to stock exchanges under SEBI Listing Regulations about a scheduled Board of Directors meeting to consider and approve audited financial results. It does not contain the financial results themselves but is a regulatory disclosure of a board meeting schedule. This falls under general regulatory announcements that do not fit other specific categories, so it is classified as a Regulatory Filing (RNS).
2026-05-21 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) regarding information under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, concerning the financial year ended March 31, 2026. It discloses the shareholding of promoters and persons acting in concert and confirms no encumbrance of shares during the financial year. This type of disclosure relates to changes or confirmations in substantial shareholdings, which aligns with the category of Major Shareholding Notification (MRQ). The document is short (1862 characters) and is a regulatory disclosure rather than a full report or announcement of a report publication. Therefore, the correct classification is MRQ with high confidence.
2026-05-07 English
Updates
Regulatory Filings Classification · 95% confidence The document is an intimation letter from Biofil Chemicals and Pharmaceuticals Limited to shareholders holding physical shares, requesting them to furnish mandatory PAN, KYC details, bank account details, nomination, and specimen signature as per SEBI regulations. It references SEBI circulars and master circulars related to compliance requirements for physical securities holders. The document is a regulatory communication informing shareholders about compliance obligations and the process to update their details with the Registrar and Share Transfer Agent. It does not contain financial statements, audit information, earnings data, or any report content. It is not a report itself but an announcement/intimation related to regulatory compliance and shareholder information updates. The document length is under 10,000 characters and primarily serves as a notification to shareholders and stock exchanges. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance-related communications that do not fit other specific categories.
2026-05-05 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter dated April 3, 2026, from Biofil Chemicals and Pharmaceuticals Limited addressed to the National Stock Exchange of India Limited and BSE Limited. It references a SEBI circular regarding a Special Window for Transfer and Dematerialisation of Physical Securities and encloses copies of newspaper notices published to inform shareholders about this facility. The content is primarily an announcement of publication in newspapers pursuant to a regulatory circular, not a detailed financial report or management discussion. The document length is about 15,000 characters, but the content is an official communication about shareholder notices and regulatory compliance, not a financial or operational report. There is no financial data, no earnings information, no management discussion, no audit report, no voting results, no capital changes, or other report types. This fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document that does not fit other categories.
2026-04-03 English
Updates
Regulatory Filings Classification · 95% confidence The document is an official communication from Biofil Chemicals and Pharmaceuticals Limited addressed to stock exchanges (BSE and NSE). It informs about a SEBI circular dated January 30, 2026, regarding a special window for transfer and dematerialisation of physical securities. The document explains the details of the circular, the timeline for the special window, and instructions for shareholders. It does not contain financial statements, audit information, management discussion, or any report data. It is essentially an announcement or intimation regarding a regulatory circular and procedural update related to securities transfer. The document length is 3104 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.